Navigation Links
Novogen Announces Establishment of Global Collaboration to Drive The Development of Drugs to Treat Brain Cancer
Date:12/20/2013

SYDNEY, Dec. 20, 2013 /PRNewswire/ -- Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma multiforme (GBM).

(Logo:  http://photos.prnewswire.com/prnh/20131220/NY36990LOGO )

The research program is focused on the super-benzopyran drug, Trilexium (Trx).

The brain cancer program parallels that of the Company's efforts in the area of ovarian cancer through its joint venture, CanTx Inc, with Yale University.

CanTx has identified a Trilexium derivative (Trx-1) as having equipotent killing ability of both ovarian cancer stem cells and ovarian cancer somatic cells, raising the prospect for the first time of being able with the one agent to kill the full hierarchy of cells within an ovarian cancer. The CanTx strategy is to bring Trx-1 into the clinic in the near-term as a generic treatment for late-stage ovarian cancer, but then to use the Trx pharmacophore to create a panel of drugs capable of killing ovarian cancer cells with specific genotypes, a further unique feature of this technology platform.

The brain cancer program has the same R&D and commercial objectives. The near-term goal is to bring Trilexium into the clinic as a generic treatment for GBM that has failed to respond to Temozolomide, the only drug approved for GBM. The longer-term goal is to identify a panel of drugs capable of providing a personalized approach to GBM chemotherapy.

The program is based on the high potency of Trilexium against GBM cells, with both GBM stem cells and somatic cells being killed at equivalent dosages.

Progression of GBM following radiotherapy and chemotherapy is believed to result from the regrowth of cancer stem cells that are chemo-resistant. Recurrent tumor cells, like their parent GBM stem cells, are highly drug-resistant and with increased aggression, accounting for the poor prognosis associated with GBM.

Dr David Brown, Novogen Group CSO, said, "The collaborative effort to date has focused on bringing Trilexium into the clinic for the treatment of GBM, and that goal will continue with the aim of bringing that agent into the clinic in early 2015."

"The expansion of the collaboration to include Cornell takes the program to the next level, which is to achieve personalized chemotherapy for patients with GBM. The objective is to identify a panel of Trx analogs that target individual GBM mutations within the genotype spectrum that characterises GBM malignancies. That data then will inform our clinical objective which is to match the best drug candidate to an individual tumor genotype."  

"WCMC has particular skills in identifying the genotype of explants from fresh biopsies of GBM tumors. We will be utilizing this ability to screen Trilexium analogs for activity against a wide range of individual tumors," Brown added.

About Glioblastoma

Glioblastoma multiforme is the most common and aggressive form of primary brain tumor. Worldwide, in developed countries, an estimated 3.5 cases per 100,000 people are diagnosed per year. Glioblastoma is one of the cancers most resistant to treatments and is associated with extremely poor prognosis. Despite therapeutic intervention (surgery/radiation/chemotherapy), glioblastoma remains a devastating disease with a median 2-year survival rate in the range of 10–25%.

About Novogen

Novogen Ltd is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN').  The Company is based in Sydney, Australia, and with a US office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc with the aim of developing personalized chemotherapy for patients with ovarian cancer.

Further information is available on the Company's web site, www.novogen.com


'/>"/>
SOURCE Novogen Limited
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Novogen Files Suite of Patents for Anti-Tropomyosin Drug Technology
2. Novogen Launches Joint Venture Aimed At Developing Drugs to Fight Ovarian Cancer
3. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
4. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
5. Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director
6. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
7. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
8. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
9. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
10. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
11. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
Breaking Biology Technology:
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):